



“Sometimes I don’t have a pulse . . . and I’m still
alive!” Interviews with healthcare professionals
to explore their experiences of and views on
population-based digital health technologies
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Abstract
Background: Digital technologies are increasingly becoming an integral part of our daily routine and professional lives, and
the healthcare field is no exception. Commercially available digital health technologies (DHTs – e.g. smartphones, smart-
watches and apps) may hold significant potential in healthcare upon successful and constructive implementation. Literature on
the topic is split between enthusiasm associated with potential benefits and concerns around privacy, reliability and overall
effectiveness. However, little is known about what healthcare professionals (HCPs) have experienced so far with patients and
what they perceive as the main advantages and disadvantages of adoption. This study therefore aims to investigate current
perceptions of HCPs towards self-tracked health-related outputs from devices and apps available to the public.
Methods: Nine HCPs volunteered to take part in semi-structured interviews. Related data were thematically analysed,
following a deductive approach with the construction of a framework based on expected themes from the relevant liter-
ature, and themes identified from the first two interviews.
Findings: The following main themes in relation to DHTs were identified and explored in detail: HCPs’ experience, knowl-
edge and views; advantages and disadvantages; barriers towards healthcare implementation and potential solutions; future
directions. While most participants were adopters of DHTs and held positive views about them, their overall experience with
patients and the technology was limited. Potential reasons for this were explored, including factors such as time/resources;
colleagues’ mindset; lack of evidence of effectiveness for practice; data security concerns.
Conclusions: The potential advantages of DHTs’ adoption in healthcare are substantial, e.g. patient autonomy, time/
resources saving, health and behaviour change promotion, but are presently premature. Therefore, future research is
warranted, focussing on addressing barriers, minimising disadvantages, and assessing the clinical value of commercially
available DHTs.
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Background
Digital technologies are increasingly becoming an inte-
gral part of our daily routine and professional lives,
and the healthcare field is no exclusion. Their use and
integration in clinical settings is well documented and
increasingly advocated in the literature.1,2 Recent
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research found that the number of health-related apps
available to the general public on major app stores
worldwide was over 318,000 in 2018, which is nearly
double what was available just three years earlier
(2015), and the overall trend suggests further increases
in numbers, diversity and features.3,4 These figures are
very much in line with the progressive increase of
smartphone ownership worldwide, particularly in the
US and the UK.4
In this context, it is therefore unsurprising that the
WHO has very recently (April 2019) released the first
version of evidence-based guidelines on digital health
interventions,5 committing to issue continuous updates
to the document as evidence progressively emerges
from research. Similarly, at a UK national level, the
NHS is currently working on a series of digital
health strategies to improve the overall healthcare ser-
vice, sustainably, such as improved and more secure
patient data handling and going progressively ‘paper-
less’ by 2020.6
It has long been established that the leading causes
of death, globally, relate to cardiovascular events –
31.7% of all deaths (17.9 million) annually.7 Thus, it
is no surprise that apps and devices specifically target-
ing cardiovascular health are prominent; a key example
and recent advancement in this field is the latest Apple
WatchVR , able to perform simple ECG tests.8
Recent studies have explored the potential implica-
tions of ‘mHealth’ (i.e. mobile health)9 integration, or
‘gap bridging’ between the personal and clinical/profes-
sional fronts, with quantitative data gathering, e.g. sur-
veys.10–12 From these, awareness of the potential
benefits (e.g. better and more frequent health parame-
ters monitoring and tailoring of related interventions)
and issues (e.g. lack of validity, reliability and scientific
evidence of effectiveness) associated with commercially
available mHealth technologies, referred to as digital
health technologies (DHTs) throughout this paper, is
evident. However, much less is known about what
healthcare professionals have experienced so far in
their everyday practice and think in this regard – e.g.
their personal or professional encounters, what their
views and thoughts are, and whether there are any
barriers towards successful implementation of DHTs
in healthcare practice that need to be identified and
resolved. Indeed, along with technological innovation
and general enthusiasm around DHTs, there is also, on
one hand, growing concern around potential issues
such as imprecision, lack of reliability and panic-
inducing false-positive diagnosis.8 On the other hand,
however, there is a perceived potential for missed
opportunities,13 due to barriers towards a constructive
and more effective implementation and use of these
technologies by front line healthcare professionals
(HCPs), such as general practitioners (GPs) and com-
munity pharmacists (CPs).
Recent qualitative work has further attempted to
shed some light on the current phenomenon exploring
healthcare professionals’ attitudes towards the adop-
tion of digital/wearable technologies by the public for
health care/tracking.14 The study findings show a sig-
nificant level of scepticism among HCPs about the use
of DHTs, though the focus of the study revolved
almost exclusively around attitudes and perceptions,
rather than experiences. Indeed, much less is known
about what HCPs find the main disadvantages, barriers
and related solutions, to be towards constructive imple-
mentation of DHTs in healthcare.
Some qualitative research has been conducted into
the use of DHTs with patients who have chronic con-
ditions, such as diabetes, obesity, Chronic Obstructive
Pulmonary Disorder (COPD) and cancer.15–20 Many of
these studies have focused on ‘end user’ or patient
experiences and the potential of DHTs. When they
have included HCP participation among the samples,
the research concern has still been that of the patient.
There has been little attention paid to HCPs’ own expe-
riences, but more on speculation about perceived addi-
tional workload21 and the need for education and
training.22 In relation to cardiovascular (CV) disease,
scoping reviews have been carried out regarding
DHTs,23 as well as commentaries24 on their potential
or scientific statements25 about self-care, which may
include DHTs, but we could identify no qualitative
studies of HCPs’ perceptions towards self-tracked CV
health-related outputs.
To gain insights into the growing digital ‘health
tech’ phenomenon, and to understand it from the per-
spectives of professionals involved, the present study
followed a qualitative approach, with the aim of inves-
tigating current perceptions of HCPs towards self-
tracked CV health-related outputs from devices and
apps available to the public, to further the existing lit-
erature and inform practice, given the gap in knowl-
edge around HCPs’ experiences. This was achieved by:
be achieved by:
• exploring current experiences of HCPs in dealing
with patients or clients concerned about their wear-
able device’s, CV health-related, output, and per-
ceived barriers and disadvantages to their use in
healthcare practice, as well as related solutions;
• evaluating HCPs’ perceived preparedness in dealing
with issues and concerns from the general public
related to digital, self-monitored CV health param-
eters, e.g. blood pressure (BP) and heart rate (HR);
• identifying potential gaps in the research around
HCPs’ knowledge, awareness and ability to deal with
the rapidly increasing popularity of self-monitoring
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apps for health and lifestyle, to be explored in future
research.
Methods
Population of interest and recruitment strategy
The population of interest for this study comprised
front line healthcare professionals (GPs, CPs and
nurses) as well as professionals in training (medical
students), intended to be sampled until achievement
of data saturation and richness and quality of data.26
No exclusion criteria were applied to this population,
nor any geographical restrictions for recruitment.
Participants were recruited via personal and profes-
sional networks of the research team, by advertising the
study on social media (professional groups, hashtags,
etc. on Facebook, Twitter, and LinkedIn), with the aid
of an advert (see Figure 1). Paper copies of the advert
were also used to advertise the study, locally, within
academic premises (Robert Gordon University and
University of Aberdeen), for snowball sampling pur-
poses, and at a conference on digital health strategies
in Newcastle – Digital Catalyst 2019, an event which
convened a mix of participants including researchers,
HCPs and potential users of research outcomes to dis-
cuss the current progress of DHTs and the future chal-
lenges that need to be addressed.27
Data collection
Data were collected between May and July 2019 in the
form of digital audio files during the conduct of semi-
structured one-to-one in-depth interviews28 undertak-
en, either face-to-face or by telephone/Skype, with the
aid of a topic guide. Digitally recorded audio files from
the interviews were then manually transcribed verbatim
by FT, on ‘.docx’ files with the aid of the pedal-
operated software Express Scribe Pro (NCH Software
Inc. Version V8.06, 2019),29 then loaded on NVivo
(QSR international Pty Ltd. Version 12, 2019)30 for
subsequent data analysis. As per protocol, focus
groups (FGs) were also to be conducted for the pur-
pose of data collection, if it were possible to bring
together more than one HCP at a time, aiming for het-
erogeneity of participants within each of them in order
to stimulate discussion around subjective views and/or
debatable aspects of the topic.31,32
Data analysis
Data analysis took place alongside the data collection
process on a framework created in parallel by FT and
HMM, based on expected themes determined from the
literature, and those that were identified in the first two
interviews. The few discrepancies between the two ver-
sions were then resolved through discussion. Appendix
1 shows the final framework adopted for data analysis.
NVivo data analysis was conducted by FT, and then
reviewed by HMM. Potential discrepancies were
resolved through discussion in this occasion as well.
Specifically, data were analysed according to the
Ritchie and Lewis method for thematic analysis.33
Upon familiarisation with the transcripts, codes were
created and themes were identified and built into the
framework that took into account those determined
from the literature. The framework was well developed
after the first two interviews, with additional codes and
themes being added as necessary from subsequent tran-
scripts. Codes and themes were periodically reviewed
for quality throughout the data collection process.
The data analysis conducted in tandem with data
collection allowed for the necessary amendments to
the topic guide prior to conducting subsequent inter-
views, which was then partly based on either sufficient
coverage of certain themes and aspects or, conversely,
the need to expand more systematically on newly
emerged themes. Figure 2 shows the indicative content
of the topic guide. Given the semi-structured nature of
the sessions, some questions were asked outwith the
topic-guide schedule, based on spontaneous conversa-
tion turns, with the intention of probing and stimulat-
ing further contextual insight. The topic guide was
designed prior to any interview being conducted,Figure 1. Recruitment advert.
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based on findings from previous literature. As inter-
views took place and data was gathered, the related
findings were used to inform necessary changes that
would ensure richness of data collection.
This study was reviewed by the Ethics Review Board
of the College of Life Sciences and Medicine of the
University of Aberdeen (Application No. CERB/
2019/4/1765 – approved 24 April 2019). All partici-
pants gave written, informed, consent for participation
and publication of quotes.
Findings
Sample
A total of n¼ 9 participants were recruited via conve-
nience and snowball sampling (see Table 1 for a
summary of sample characteristics and labelling used
for quotations). Of the n¼ 8 individuals contacted and
invited directly to take part in the study, 50% (n¼ 4) did
partake. Overall, the sample comprised: n¼ 5 medical
professionals (n¼ 3 GPs and n¼ 2 medical students);
n¼ 3 nursing staff (n¼ 2 registered nurses and n¼ 1 aux-
iliary nurse/clinical change assistant for NHS Digital)
and n¼ 1 community pharmacist/academic lecturer.
The age span of the sample was between mid-twenties
and late fifties, all but two from the UK. The single
participant from the US was recruited as a personal con-
tact, a medical doctor expert and actively involved in
global health action, invited to take part in the study
due to the worldwide relevance of cardiovascular dis-
eases, and to gain some insight into DHTs in terms of
practicality and feasibility of their implementation in set-
tings other than a high-income country, such as the UK.
All but two interviews were conducted face-to-face. One
interview was conducted over the phone (participant
008) and another one via Skype (participant 007).
As mentioned, FGs were also supposed to be con-
ducted. However, despite a successful outreach of the
advert through social media (one tweet managed to get
over 1,500 impressions), the steady-but-slow progres-
sion of participant enrolment to the study meant there
was never a sufficient number of participants available
at once to run focus groups during the study’s data
collection phases.
HCPs familiarity, experience and perceived
knowledge with DHTs
Overall, most participants did have some familiarity
with DHTs for personal use, primarily apps and
Table 1. Participants details.
Participant number Role as HCP Quotation labels Nationality
001 Pharmacist Pharmacist UK
002 Medical student (4th year) Med student UK
003 GP GP and academic researcher UK
004 Medical student (junior doctor) Med graduate UK
005 GP GP and academic lecturer UK
006 Nurse Nurse Greece
007 GP and global health (GH) expert GH expert US
008 Auxiliary nurse and NHS digital employee Aux nurse UK
009 Nurse Nurse and academic UK
Topic guide overall content
- Intro/HCP background
- Personal opinion/knowledge about DHTs 
- Experience with paents and their DHT devices and 
outputs
- Perceived DHTs advantages and disadvantages
- Perceived barriers for DHTs implementaon in 
healthcare pracce
- Soluons to overcome barriers
- Consideraons for the future of DHTs
- Disseminaon ideas
Figure 2. Topic guide indicative content.
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wearable devices, for a variety of health-related pur-
poses and tracking – sleep, running, heart rate moni-
toring, mindfulness, etc.
‘I have used FitBits before. I’ve also used My Fitness
Pal, but that was mainly just for, like, recording what
I’ve eaten so . . . yeah, and I find them really useful actu-
ally for monitoring . . . ’ [Med Student].
‘Yeah, I mean, I am familiar with the apps. I think self-
monitoring’s one of the main components of health apps.
I guess I kind of think of the difference between fitness
trackers, cause a lot of people wear fitness trackers, and
then apps that people have downloaded to deal with a
specific condition.’ [GP and Academic Researcher].
‘I’m using a physio app myself called Reach – you gen-
erally need it for about 10 weeks; you fill it in – it asks
loads of questions about you, pain, type of pain and
where it is – and then they device some exercises for
you and for those exercises, there’s a video for you to
watch so you can replay it’ [Nurse and Academic].
‘Uhm . . .what else am I using . . . ? I think Headspace, you
know, for like meditation . . . sometimes I use the ‘Heath’
app for like counting steps but probably use my watch a
bit more for that’ [GP and Academic Lecturer].
However, most of them also had very few experiences
of dealing with patients wishing to discuss their cardio-
vascular health status based on outputs from their own
devices and apps.
‘So, yeah, we’re not really knowing about that, we’re not
really promoting it and when I’m saying, earlier in the
interview, that there’s a lot of problems like weight man-
agement, obesity and things, you know, actually, there’s
probably huge scope for us to be embracing this a bit
more! Uhm, but I guess it’s also new, isn’t it? Like, we
don’t have the evidence – it’s not becoming part of pop-
ular practice or culture’ [GP and Academic Lecturer].
The med students also stated that digital heath tech-
nologies are not very much, if at all, part of their train-
ing programme.
‘[I am] only vaguely [familiar with digital health apps
and devices], but I couldn’t think of any specific exam-
ples or anything so I think there’s a lot out there that I’m
not aware of and probably should be more aware of but
it’s not something that is in our curriculum or anything
like that so . . . ’ [Med Student].
Although personal use of digital health tech was quite
popular among the participants, their experience as
HCPs dealing with patients presenting with similar
data was, sometimes to their own surprise, very modest.
‘I’m thinking about my job as a clinician . . . I actually am
quite surprised that I haven’t had more patients come to
me with problems or issues [associated with digital read-
ings/outputs]’ [GP and Academic Lecturer].
‘I’ve had this maybe 2 or 3 times. So, my patients tend to
be [. . .] quite an affluent group. [. . .] And a lot of my
patients, hardly any of them smoke, a lot of them do
exercise, uhm, cardiovascular disease isn’t one of the
main problems in the practice and a lot of people take
in active uhm interest in their cardiovascular health.
[. . .] And a lot of them do wear smartwatches [. . .].
And I’ve had a couple of scenarios where they’ve got
unexpected HR readings from them? [. . .]. [I] had one
gentleman who was concerned about his HR readings on
his watch and . . . I can’t remember actually if he was too
fast or too slow [. . .]. One of my colleagues had referred
him to cardiology, and then he made the decision, on his
own, that actually he was so well . . . and all those tests in
the practice, ECG and heart rate, had been fine, that he
decided not to go to the cardiology appointment’ [GP
and Academic Researcher].
A main reason provided as to why the participants’
experience with patients and their digital health gear
was limited, despite the evident proliferation on the
market and personal ownership, was the fact that, over-
all, the phenomenon is perceived to be at early stages.
‘It’s quite an emerging area of practice that we haven’t
quite caught up with’ [GP and Academic Researcher].
‘Come to think of it, I’m highly surprised that that is not
the case, and we’ve discussed already the reasons why – I
wonder if there’s a bit of lag with this’ [i.e. between the
technology being finally available, and patients/health-
care providers making ordinary use of it]. [GP and
Academic Lecturer].
‘I think it’s just . . . a lot of digital technology’s still in its
infancy?’ [Med Student].
HCPs attitudes towards patient-owned DHTs
The overall attitude towards patient-owned, or ‘com-
mercial’, digital health devices and apps was largely
positive, despite the significant lack of experience in
dealing with it personally.
‘It’s the way forward! And people need to stop saying ‘oh
but I’m used to pen and paper’ well – tough! Cause pen
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and paper is inefficient and it’s taking you away from
your patient – stop what you’re doing, pick up an iPad,
or a computer or a laptop, and get on with it and with
your patient! [This would result in] more time with your
patient! Patient care is the beginning and the end of
everything we do, so therefore that should be our
focus!’ [Aux Nurse].
‘I think it would be a useful tool to start conversations
with healthcare professionals (HCPs) regarding results/
health in general.’ [Pharmacist].
Only one participant felt that these technologies could,
potentially, be more of an issue and hindrance to
healthcare practice, than something beneficial.
‘With the general public who probably don’t have that
level of [medical/scientific] knowledge it’s really chal-
lenging and you need to provide a lot of background –
you need to go right at the start and . . .we just don’t have
time or capacity to do that. I think it would also lead to
so much unnecessary anxiety and worry. [. . .] Uhm, I
think we need to just be really careful that the line is
sitting on that side – that it’s a helpful thing for patients,
and it doesn’t just become burdensome, it doesn’t become
extra workload for doctors’ [GP and Academic
Lecturer].
Digital health and the online environment
Participants were also invited to reflect on digital
health aspects in terms of information that patients
may gather from a simple online search. Indeed, par-
ticipants have often had experiences of seeing patients
who had previously searched their symptoms online
and then sought expert advice with a ‘self and pre-
made’ diagnosis. Quite often, participants found the
patients’ self-gathered information either to be the
unrealistic extreme worst-case scenario of the correct
condition or even the wrong one completely.
‘The only disadvantage I would have would be somebody
who sits at home and has all of these . . . like they go on
the internet, they go on apps and self-diagnosis, where
they could be completely wrong – I’ve seen it happening
when I’ve done a shift on A&E’ [Aux nurse].
‘I think there’s an emphasis on serious worst-case sce-
nario-thinking on searches’ [GP and Academic
Researcher].
A recurring theme in this context was the participant
concern about the reliability of the online source of
health knowledge and how this can, sometimes, not
only misinform but also cause distrust in patients
towards their healthcare providers.
‘I find that people do come with ideas about conditions or
treatment that they have found online. Sometimes this is
helpful, although not always. It is sometimes difficult to
change opinions on some issues like antibiotics requested
when not necessary’ [Pharmacist].
‘I would say about, uhm, 20 to 25% of the time patients
come with inaccurate information. [. . .] I mean,
Facebook is the devil when it comes to medical informa-
tion – everybody thinks they’re an expert on Facebook,
uhm, and same thing with these online blog where people
form these communities and start talking about nonsense
– like, they start talking about vaccines or ‘this drug is
harmful’ ‘that drug is harmful’ without knowing any kind
of evidence base behind that’ [GH Expert].
By contrast, one of the participants was, cautiously,
more optimistic and trusting of their patients’ ability
to be critical about the information gathered online.
‘My gut feeling is that people are relatively sceptical
about online resources – they sort of do a bit of scoping,
to see what’s out there, and use it as part of their
decision-making but not all of it and usually people are
quite sensible about knowing that the internet is not a
definitive and trustworthy source of information’ [GP
and Academic Researcher].
Questions related to digital/online health also led to the
understanding that in the UK the NHS has started a
database of ‘approved apps’ with the aim of ‘helping
patients and the public to find trusted health and well-
being apps’, assessed by the NHS and deemed clinically
safe.34
‘Well, I think, if you’re going to be using apps in health-
care then you need to have some kind of “central library”
of approved apps. And I think that’s what the NHS
started doing. So they’ve got the “NHS apps library”,
[. . .] I think that’s a good kind of framework in that
there’s people within the NHS assessing the suitability
of apps and how accurate they are so then people can go
online and see “oh this has been approved, so I’m happy
to use this”’ [Med Student].
Meanwhile, the NHS has also started some initiatives
aiming to move towards a ‘as digital as possible’ envi-
ronment within their systems and hospitals, by a set
deadline.
‘[. . .] NHS digital – this team works around GDE,
Global Digital Exemplar trust, from Newcastle. So we
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got £5 million from the government and we added anoth-
er £5 million, which made this trust as digital as possible
by the year 2020, [. . .]. And what we need to do as part
of the “NHS digital” focus is to make the NHS at least
80% paper-light, by 2020. We are never going to become
completely paper-light because we always need business
continuity plans. But that’s in all aspects, whether it’ll be
cardiology, elderly care, mental health, medicine, sur-
gery, everywhere needs to become more digital and also
so we can then care with things like other trusts – GP
practices, the community teams, etc . . . ’ [Aux Nurse].
Reliability concerns
Concerns associated with overall reliability of the tech
available to the general population (such as validity,
accuracy, calibration), both in terms of intrinsic
issues and limitations of the tech, as well as user
error, were a theme which frequently emerged among
the participants.
‘I’m not sure what the [manufacturers’] standards are –
you know, heart rate, for example, [or] pulse – I don’t
know what they use to determine whether their devices
are accurate or not. Because I know, from my use that,
you know, sometimes I don’t have a pulse . . . and I’m still
alive [laughter]. Something’s not quite right. And whether
that’s the device itself, or the user – user error might con-
tribute to some significant discrepancies between what the
result actually is and what appears on screen’ [Pharmacist].
The current approach to solving the issue was, virtually
across the board, to double-check the readings from
the personal devices with gold standard and validated
professional equipment.
‘I would be wary of the readings obtained from these
devices due to lack of calibration, reliability, potential
for user error, however, may direct individuals to
HCPs for measurements taken using calibrated equip-
ment’ [Pharmacist].
‘I think I’d be a little apprehensive, because I don’t know
if it’s always accurate, I guess that it is, but, it’s subtle
[. . .] And if, like, they’re saying ‘oh my blood pressure’s
like “this” on my smartwatch’ . . . I’d want to check it
myself, rather than put my, like, approval on some
piece of technology’ [Med Graduate].
One of the participants also provided an alternative expla-
nation as to why there may be discrepancies in outputs/
readings from a digital device and the actual or alleged
health status of the individual using it, based on our
current understanding of what’s ‘normal and healthy’,
which may be limited, and consequent cut-off values.
‘[. . .]and I said to [my patient concerned about self-
monitored heart rate readings] “a) we don’t know if
they’re 100% accurate . . . ”, you know, his clinical exami-
nations had been fine; he was exercising at quite intensities
without any symptoms “ . . . so you’re quite at low-risk”.
The other thing that I questioned in my head is the way
we’ve developed our reference ranges for things? Or ideas
about “norms”? I wonder if there’s any time in the history of
medicine when we’ve taken literally millions of healthy indi-
viduals and have measured their HRs over extended periods
of days, months, years’ [GP and Academic Researcher].
Perceived advantages of patient-owned DHTs
Participants were actively invited to consider potential
advantages of DHTs available to the public. In this
context, the advantages that emerged during conversa-
tion were: a) behaviour change; b) aid conversation
with HCPs; c) patient autonomy/minimising the
‘white coat syndrome’/time and resources-saving.
a. Behaviour Change
i) ‘And I think you can encourage people! If you set small
goals, like ‘oh you should walk six-thousand steps a day’
then if it’s achievable for that person, then they’ll want to
do it, and then you can increase the goals’ [Med Graduate].
ii) ‘It motivates you to get more active [. . .]. And you
know, if you do one lifestyle change, then other changes
will start to follow. So if you start keeping track of your
health, and it says that your HR is a bit high, so: you
take actions to lower your heart rate; uhm, you may
change your diet as well; you go to sleep earlier; you
relax a bit more. You get more conscious about your
general health and I think that at the end you learn to
love yourself better, to respect yourself better’ [Nurse].
b. Aid conversation with HCPs
‘I think it would be a useful tool to start conversations
with healthcare professionals (HCPs) regarding results/
health in general’ [Pharmacist].
c. Patient autonomy/minimising the ‘white coat syn-
drome’/time and resources-saving
i) ‘I think it would be really useful, because I think there
are only so many things you can monitor in a hospital
[. . .]. I think especially if you wanted to monitor things
over a certain length of time, it’s much easier if the
patient has control of that and they can do it themselves?
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So, it’s definitely something I would be open to listen and
talk to the patient about’ [Med Student].
ii) ‘I think [with this kind of tech] you can get measure-
ments over a much greater time period and, as well, when
people come into hospital [. . .] they might get nervous so
it’s difficult to insure you are getting accurate readings of
things, whereas if you just give them something that they
can track within their daily life, you know you’re getting a
much more accurate representation, especially when it
comes to things like cardiovascular heath, because with,
obviously, if people are nervous, sometimes their BP can
rise, so if you’re measuring that outside of a hospital set-
ting, then you know it’s more accurate’ [Med Student].
With patient autonomy with health tracking, the
potential consequent advantage of relieving some pres-
sure on the healthcare system also emerged.
iii) ‘But I think, overall, definitely, there’s a lot of poten-
tial and it could free up a lot of NHS time and resources,
which is obviously a huge problem at the moment . . . ’
[Med Student].
One participant, based on a personal experience as a
patient themselves, had particularly positive views in
terms of patient autonomy and the ability to self-monitor
and keep track of their own health at any time. The fol-
lowing quotation was inspired by a question about a recent
smartwatch able to perform a single-lead ECG reading.
iv) ‘I’ve got a heart murmur [. . .] [and] abnormal heart
rhythm, but only occasionally so if I had an ECG it would
be fine because it wouldn’t be when the thing is happening.
But I bought myself a heart monitor; it’s just a small thing
and you hold it [between your hands sort of gesture] and
it comes up with a small tracing [which the GP was happy
about, though it couldn’t provide good or long enough
readings]. [. . .] And then I saw the watch . . . and that’s
what I want for Christmas! Because [. . .] then I can give
my GP the data and then they can decide what needs to be
done. So I know that my GP would be willing to take
something like that because [we already had similar con-
versations]. But I obviously can’t just go in to the doctors
because [. . .] by the time I’ve got an appointment it [my
ECG reading] would be OK again! [. . .] And I’m not ill
enough to go to A&E or present anywhere, or I don’t feel
it would be appropriate so something like this would be
actually ideal’ [Nurse and Academic].
Perceived disadvantages of patient-owned DHTs
Participants were also invited to consider potential dis-
advantages of DHTs available to the public. Some of
which have already been presented in previous sections
of the findings, i.e. reliability concerns of both digital
health devices and sources of information. Specifically,
this section will contain disadvantages associated with
DHTs that surfaced upon active prompting during
interviews. Overall, these can be grouped as: a) anxiety
and data obsession; b) patient autonomy and digital
tech illiteracy; c) time and money wasting; d) data secu-
rity and manufacturers’ agenda vs healthcare agenda.
a. Anxiety and data obsession
i) ‘Our obsession with technology, you know, as a soci-
ety, or inability to switch off from what’s going on –
being over focused on numbers and data. Uhm, from a
mental health perspective, you know, maybe I’m not
enjoying my run, for example, because I’m looking to
see what my watch is telling me about the speed that
I’m going [and] I’ve missed the fact that there’s . . . a
new species of bird next to me! Or the fact that the
sun’s shining or there’s waves crushing . . . I’m actually
focussed on whether or not my lap time is OK or whether
or not I’ve beaten last week time. Uhm, I’m working
towards numbers and focused on technology. [. . .] you
know, the other elements of life are becoming less impor-
tant to me, if I’m focussed on numbers and data and self-
tracking’ [GP and Academic Researcher].
ii) I think it [self-tracking and patient-owned DHTs]
would also lead to so much unnecessary anxiety and
worry. In the population, generally, the levels of anxiety
and, uhm, stress are exploding!’ [GP and Academic
Lecturer].
b. Patient autonomy and digital tech illiteracy
i) ‘The only disadvantage would be if, because of an app,
somebody didn’t dial 999 or get the help that they needed
[. . .] [Nurse and Academic].
ii) ‘I think maybe [. . .] the healthcare professional can’t
monitor how it’s being used [patient’s DHT] or if it’s
being used accurately, [. . .] someone else could have
been wearing it or they might have been using it
wrong? So there’s that kind of checking by the healthcare
professional is . . . you’re less able to do that. It’s down to
how the patient uses it and whether they are using it
correctly’ [Med Student].
iii) ‘There is a reason why people go to med school for
many years – there is only so much that digital apps can
do. [. . .] it probably gives you information, but it won’t
help you process that information which is what a clini-
cian can do so then [patients] rely and take the
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information coming from digital sources as ‘final’. Uhm,
[I would suggest, instead] use that to question and have
a discussion with your clinician’ [GH Expert].
c. Time and money wasting
‘And the other concern [is] the influence on our health
services in terms of resources. [. . .] If somebody has an
appointment with me to discuss the finer points of the read-
out from their Apple watch, uhm, then there’s somebody
else that day that is not being seen! [. . .] the NHS is a
limited resource [. . .]. We don’t know if it’s good value for
money . . . it may well be, I don’t know. But the cost and the
resources taken to consult with, by enlarge, healthy people,
about data that they are monitoring [pensive, sentence left
open] . . . ’ [GP and Academic Researcher].
d. Data security and manufacturers’ agenda vs health-
care agenda
i) ‘And the other thing is about our data. Patients may
feel that they are being watched, that they are being
recorded and, uhm, too much information about them
is out there’ [Nurse].
ii) ‘Another [disadvantage] is the security of data, uhm,
which is a considerable concern at the moment, especially
with regards to health data. [. . .] my device records
when I sleep, how many steps I’ve done in a day . . . but,
not everyone is going to be comfortable to necessarily
share that information with their own device. And what
happens to that information when it’s transmitted some-
where else? Would someone else have access to it? And
how can it be used? And are businesses using this infor-
mation as a method of currency?’ [Pharmacist].
iii) ‘In my opinion, there are two different approaches to
technologies, research and implementation. And there’s
different individuals who are making technology and they
all have slightly different agendas. So Apple, obviously,
huge multi-national organisation, who are a commercial
organisation – they want to make money out of products.
Academic organisations are interested in research and
what might help and what might work. [. . .] And then,
if they are effective, and not harmful, then implementing
them. But there’s no onus on commercial companies to
look at all the intended and unintended consequences
before they implement. So you’ve got this miss-match
between, sort of, research and implementation where
lots of things are being implemented without efficacy
testing. The opposite is true in academia – lots is being
tested and not implemented!’ [GP and Academic
Researcher].
Perceived barriers towards implementation in
healthcare practice
The significant lack of experience in dealing with
patients and their DHTs, despite the evident increase
in their popularity, led to the understanding that some
factors may be hindering their incorporation in health-
care practice. As this became more evident, around
midway through the data collection process of this
study, participants were actively, and more systemati-
cally, asked to consider main/perceived barriers
towards commercial DHTs implementation in health-
care practice. This resulted in the identification of a
variety of different issues: a) patients’/HCPs’ digital
literacy and mindsets (both often age-associated); b)
costs, inequality, lack of resources and infrastructure;
c) fast obsolescence of the tech; d) lack of evidence of
effectiveness for clinical implementation.
a. Patients’/HCPs’ digital literacy and mindsets
i) ‘People [patients] that are older, who are not familiar
with the technology and they don’t know what FitBits are
[. . .], they might be feeling a bit hesitant to use [them].
So if their GP said “can you wear this throughout the
week?” They might think “why[. . .]? I don’t know what
to do with this”. So, I think, trying to overcome that
barrier is really important’ [Med Student].
Conversely, one of the older participants did address
the age/digital illiteracy issue, however, they did not see
it to be nearly as extensive or ‘across the board’.
ii) ‘Older people might wouldn’t embrace [DHTs]. But I
do think, as well, that it does depend on the individual.
We sort of tend to think that older people don’t use the
technologies, but you know, sometimes they do! And
they’re on Facebook and they’re doing Skype and using
things so they might be willing [to adopt the tech more],
so I think that [it’s more about] personality perhaps,
than age!’ [Nurse and Academic].
iii) ‘Staff resistance! [is a barrier]. [. . .] It’s not in their
culture – it’s in their life [as they use health apps them-
selves], but it’s not [. . .] protocol. And they are not
educated as well to do so – there are no guidelines’
[Nurse].
iv) ‘I think health professionals are threatened some-
times by emerging technologies, uhm, and they sort of
[say] “oh, don’t google that” or I’ve seen mugs with,
uhm, “don’t confuse my medical degree with your
Google search” and things like that. But actually, we
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probably ought to be focusing on the powerful benefit’
[GP and Academic Researcher].
v) ‘Most of the older generation of physicians still see
digital as something that is a fad, [. . .] new and some-
thing not that reliable because they still believe that med-
icine is all person-oriented. Which is true to some extent!
[. . .] but digital technologies these days can make a lot
of things streamlined and organised so . . . ’ [GH Expert].
b. Costs, inequality, lack of resources and infrastructure
i) ‘Uhm, I think one of the main things for me would be
the fact that these devices aren’t available to everyone?
That sort of creates some inequality. So, if we’re going to
use self-tracking, are we going to rely on people having
their own devices such as an Apple Watch, Fitbit or
whatever? And, not anybody is going to be able to
afford that’ [Pharmacist].
Whilst inequality, in terms of access/ownership of
DHT, did come up on some occasions when consider-
ing barriers, some participants also reflected on the fact
that, in reality, now virtually everyone owns a mobile/
digital device.
ii) ‘And there might be a bit of inequality with respect to
finances and data coverage and . . . but I think smart-
phone usage is permeated in society at every level and
even in young people and children’ [GP and Academic
Researcher].
iii) ‘Nobody thought Instagram and Facebook would
spread so fast in Africa but, look at it – everybody is
on Instagram and Facebook. If you show the world the
potential of any app, people will jump on to it. it’s just
making sure that you have . . . that you eliminate the
infrastructure barrier – that’s the key!’ [GH Expert].
And, indeed, infrastructure was another main barrier,
both in terms of obsolete IT systems (developed world),
as well as more basic, yet fundamental, aspects such as
reliable internet and power (developing world).
iv) My experience of IT in the NHS [. . .] has been,
uhm, very unfavourable. [. . .] the IT systems, they are
slow, they’re backward, they never work that well’ [GP
and Academic Lecturer].
v) ‘Uhm, not having good infrastructure and [. . .] I
mean, at the end of the day, for anything digital to
work you need reliable internet, you need reliable
power [. . .], which are the basic things that need to be
taken care of before . . . uhm, those are the main big bar-
riers – infrastructure’ [GH Expert].
c. Fast obsolescence of the tech
‘The other thing, I suppose, is that technology is devel-
oping so quickly – if we were to invest in the technology,
how long is it going to be before it’s obsolete and needs to
be replaced?’ [Pharmacist].
d. Lack of evidence of effectiveness for clinical
implementation
‘I think there’s a real need for some evidence in the area,
particularly about what we do with abnormal readings
[from patients’ own DHT devices] [. . .] for example, if
the patient had found a tiny short run of atrial fibrilla-
tion, for example, of their ECG reading, and they’ve been
completely asymptomatic – is that equivalent to us find-
ing it on a pulse check or an ECG in the practice?’ [GP
and Academic Researcher].
Suggested solutions to overcome disadvantages and
barriers
Once barriers were identified, participants were asked
to think of potential solutions to overcome them. These
will not entirely match the previous section because, as
mentioned, a more systematic approach to barrier/
solution finding was not pursued from the start of
data collection.
These solutions are grouped as follows: a) interven-
tions on DHTs for official and trusted reliability; b)
interventions on HCPs and patients to facilitate the
understanding of rationale and purpose of DHTs; c)
data security solutions; d) infrastructure solution.
a. Interventions on DHTs for official and trusted
reliability
‘There’s a massive gulf between what we’re using at the
moment and what’s available [GHT-wise]. So I think the
first step would be to give the clinicians better access and
let us start to be using digital technology and then,
maybe when we were getting more comfortable with it
and happy that it was reliable and validated [. . .], maybe
[. . .] patients could upload their input data sort of on
NHS-type systems or something? That might be a better
way around it, rather than patients individually holding
these devices that nobody is calibrating or validating, and
then giving us that data’ [GP and Academic Lecturer].
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b. Interventions on HCPs and patients to facilitate the
understanding of rationale and purpose of DHTs
i) ‘Uhm . . . educate staff more. Maybe we should have
presentations/lectures on digital health. Maybe the Uni
could play a role to make us familiar. Because, not only
the general population needs to be more educated, but
also the healthcare professionals! And how to use the
apps properly and which apps to use and how not to
let, on the other hand, apps to take over our life!’ [Nurse].
ii) ‘So maybe could do group sessions where healthcare
professionals would be teaching individuals how to use
the technology, and to understand why they [patients]
are being monitored and what it’s for and what the ben-
efit of that could be’ [Med Student].
The issue regarding data security concerns did not
result in specific, concrete, solutions being found.
However, it was considered that it may be more of a
manufacturer duty to provide a safe online environ-
ment for data sharing.
c. Data security solutions
i) ‘Data security is always going to be an issue. [. . .] PII
[personally identifiable information] has to be securely
protected; it is always going to be an issue. But there
are . . . I mean we have all of these apps, banking is done
on apps, I do all my stock market on apps on my phone!
So will there be security concerns? Yes, but whoever is
developing the apps, I’m sure are capable of addressing
those security concerns’ [GH Expert].
Similarly, to avoid potential liabilities upon data
breaches, a participant added the following:
ii) ‘I think confidentiality [issues] can be solved by
somebody signing an agreement to be sent info via
given channels’ [Nurse and Academic].
d. Infrastructure solutions
‘Uhm I think the cell phone technologies are better suited
in Sub-Saharan Africa than any other matters, because
cell phones are widely used – everybody seems to have
cell phones these days, especially smartphones. There’s
reliable 3G in most parts of the world, uhm, it may not be
4G or 5G, but at least 3G is quite present. So taking the
route of using cell phones to develop your digital tech-
nologies is the way to go rather than relying on any other
digital sources. People are on their phones a lot! And
keep it simple – anything complex that requires a lot of
internet bandwidth is not going to be used at all because
it won’t work – it has to be simple and provide the basic
information in the native language’ [GH Expert].
The future
Participants were also asked what they thought the
future of patient-owned DHTs and cardiovascular
healthcare may be like. The answers ranged from com-
plete optimism about successful incorporation of the
technologies in healthcare, to some level of scepticism.
‘[in the future] you may be able to use technology to
empower patients to look after their own health. And,
also, relieve the burden on the NHS, because if you’re
able to take that kind of bottom tear of people coming
to the GP with problems that they could have looked
online [or] on reliable apps and found out the answer
to, then that will take away that percentage of people,
[to] then free up GP appointments or any premises for
people that actually need medical attention. So it’s defi-
nitely like a really bright prospect for the future, we just
need better education!’ [Med Student].
‘Well, I hope [in the future DHTs will be] very useful and
very beneficial, time-saving, effective, uhm . . . partnership
– more of a partnership approach to health; patients feel-
ing autonomous with their health, getting their results and
what they’re going to do with them. Uhm so that’s what I
think I’m very positive about apps and how they might be
used in healthcare’ [Nurse and Academic].
‘Uhm, not sure what it will look like. I guess it could look
like two things. [Either] everybody having their watches
and their phones and recording things, but nobody [. . .] is
really understanding why they’re doing that, or under-
standing what that means, [and interpreting] that data.
And that is what I’m worried about – [. . .] where would
that work fall? Who’s gonna do that work? Uhm, or it
could look like the NHS or clinicians have more control
over that and we’re able to involve people in using apps or
digital technology that is approved or validated or ones
that have resources [. . .] to help people with it [. . .].
[And] I think [meanwhile until the future of GHTs’
will be clearer, HCPs’ attitude should be] one of healthy
scepticism, recognising that this is promising. Recognising
that it’s great that people are taking an interest in their
health. Recognising the limitations and the fact that the
evidence hasn’t caught up’ [GP and Academic Lecturer].
Both GPs (participants 003 and 005) also saw little
value in current cardiovascular health self-tracking.
‘And I think the big question that needs to be asked [is] –
if you’re measuring pulse or BP or taking an ECG – why
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are you doing it? Why would you do that? [. . .] We
shouldn’t be blanket ECG-ing the whole population
with Apple watches, because then we’ll just end up with
lots of problems and lots of unnecessary over-
investigation, over-diagnosis, completely moving away
from the message of realistic medicine, which is the direc-
tion of travel that we know and most set out for us at the
moment’ [GP and Academic Lecturer].
Nevertheless, participant 003 also considered the fact
that, regardless of their value in healthcare practice,
patient-owned DHTs are effectively generating an
unprecedented amount of health/physiology-related
data, which could potentially result in contribution to
the current medical knowledge.
‘Do we definitely understand the normal reference ranges
[for heart rate]? And will our understanding of normal
reference ranges change with big data from huge fitness
companies? We might actually find something surprising
about human beings and the way that their heart rate is!’
[GP and Academic Researcher].
Discussion
We explored HCPs’ experiences of and views on com-
mercially available DHTs, e.g. smartphones, smart-
watches and health apps. The rationale was their
perceived potential for integration into healthcare.
We were especially interested in views on their value
for CV disease. HCPs described current knowledge and
experience and offered insights into barriers towards
(and potential solutions for) constructive implementa-
tion of DHTs, where patients are already using them to
self-manage and track aspects of their health.
Experiences, knowledge and opinions
Overall, participants showed levels of personal interest
in and familiarity with DHTs as users themselves,
which is a potential bias in the sample (explored further
below). Despite some scepticism regarding overall reli-
ability, their use of DHTs is varied, covering different
aspects of health: fitness, mindfulness and specific med-
ical condition management. This is unsurprising,
given the widely documented increase in these technol-
ogies’ popularity within society.10,35,36 However, their
proliferation has not increased HCPs’ experiences in
dealing with patients enquiring about them. This sur-
prised them.
Reflecting their general lack of experience, partici-
pants felt their knowledge or preparedness to deal with
patients enquiring about personal digital health devices
and data is limited, because there are no clear and
official guidelines for practice, or professional training
available. This conflicts with the NHS push towards
hosting a database of ‘approved apps’ among the vast
array of choices available to anyone,34 suggesting
awareness of, interest in and commitment to the grow-
ing phenomenon within the UK healthcare service.
Given the current ‘early stages’ of DHTs, however,
there could be a ‘lag’ between patients’ informal use
of them, and subsequent more formal enquiries
with a HCP, which in turn may justify the need for
training and clearer guidelines for practice in the fore-
seeable future.
Participants, by contrast, detailed many experiences
of patients presenting with information gathered online
about their medical conditions and related treatments
or courses of action. They often felt that patients
focused on the ‘worst-case scenario’, causing unneces-
sary panic and sometimes even distrust in the health-
care provider. Patient use of the internet as a source of
medical information has been a well-established phe-
nomenon for decades now.37–39 A similar trend may
have just begun with DHTs. 3,10,40
Despite lack of experience and concerns about pro-
fessional engagement with commercial DHTs, opinions
around their use in practice were positive in general. The
predominant attitude was one of openness to discuss
patients’ issues and concerns about DHTs’ outputs,
albeit with caution, as little value was seen in overly
frequent self-tracking of health-related parameters.
Advantages, disadvantages and concerns
Several advantages and disadvantages associated with
DHTs were identified. These were in line with current
literature on the topic, such as behaviour change poten-
tial, patient autonomy and consequent time and
resources implications.41,42 What is particularly inter-
esting about our findings is how often the same aspect
was seen as a potential advantage by some participants,
and a disadvantage by others. An example of this is
‘patient autonomy’. Some participants believed that
patient autonomy could lead to some level of self-
care and self-monitoring by patients through DHT
use, which may result in fewer GP appointments
being booked, therefore some pressure relief on a
national healthcare system known to be both financial-
ly and timewise burdened.43,44 Clearly, from this point
of view, patient autonomy would be an advantage,
saving time and resources. Other participants on the
other hand saw the issue from a different angle as
they felt that the implementation of commercial
DHTs in routine healthcare could instead result in
extra trouble-shooting (of any technological malfunc-
tion or patients’ inability to operate it) whose solution
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would become the HCPs’ responsibility, thus, extra
time and resources being employed, i.e. a waste.
A concern that stood out most was that of patient
data security. The two digital realms of the healthcare
system vs. private companies, it was felt, are conceived
with differing ultimate priorities; respectively – health
care/promotion and profit. These concerns are quite
legitimate, as precedents of data security issues are fre-
quent in many personal and professional sectors, and
the potential for patients’ data leakage has also been
evaluated and documented, even among the NHS Apps
Library.45,46 In this context of diverging agendas and
interests between healthcare system and private digital
companies, we also explored potential DHTs’ reliabil-
ity issues and, as shown, concerns about them were
prominent. Similarly, the overall trend of smartphone
ownership might result in an increase of app use for
health-related queries; unlike a simple and relatively
anonymous web search, these apps tend to require a
priori, and further generate, a significant amount of
personal information which may well be of a sensi-
tive/confidential nature,47 thus further justifying the
participants’ concerns associated with data security.
Barriers and solutions towards healthcare practice
implementation
Among the barriers identified for constructive imple-
mentation of commercial DHTs in clinical settings,
three of them require particular attention. First,
inequality concerns – it is no surprise that DHTs, par-
ticularly wearables, are quite costly and not accessible
to everyone. Moreover, those who cannot afford the
technology due to financial restrictions, arguably, are
the ones who could benefit the most from any form of
health intervention, since poverty is a well-known indi-
cator of poorer health outcomes.48,49 Unfortunately,
providing patients with the necessary tech for health
purposes under the NHS (or equivalent elsewhere) is
financially unrealistic.
Second, in a developing context, such as Sub-
Saharan Africa, DHTs also face a significant challenge
for implementation in healthcare, given the significant-
ly greater infrastructural barriers resulting in unreliable
power and online access. The solution provided by the
‘GH Expert’ participant in this regard was quite simple
and effective – anything wireless and battery operated
could be a sufficient workaround since, contrary to
general belief, ‘everyone seems to be on their [smart]
phones these days’ and ‘there is reliable 3G [internet
coverage] in most parts of the world’. Interestingly,
this could also potentially solve the inequality concerns
in parts of the developed world, as smartphone owner-
ship has been progressively increasing and become
nearly ubiquitous in (developed and developing) socie-
ties, more so than wearables.50
Third, some participants identified a significant lack
of evidence of efficacy of DHTs for clinical practice
and, consequently, a lack of clear guidelines to
follow. This is strongly supported by recent findings
in the literature that invite more in-depth research on
the topic.51,52 Ideally, the evidence should come from
pragmatic clinical trials, in order to assess the impact of
interventions on objective outcome measures as rigor-
ously and reliably as possible.53 Parallel (nested) qual-
itative assessment of the experiences of both HCPs and
patients involved would also be undoubtably beneficial
to gain valuable insight into potential barriers, pros
and cons of DHT-based interventions.54
Further considerations and recommendations
This study covered a variety of different themes within
the current mHealth debate about DHTs and their
implementation in healthcare. The original aim and
objectives were to consider the phenomenon of DHTs
increase in popularity with a focus on cardiovascular
health and disease management and prevention, from
HCPs’ points of view. However, the lack of experience
of our participants in dealing with patients and their
personal devices and data meant participants were
more comfortable discussing the phenomenon in gen-
eral terms. As a result, the cardiovascular aspect
throughout data collection became more of an occa-
sional topic, rather than a main component. This
allowed the issue to be explored in broader terms, war-
ranted by the realisation that patient-owned DHTs are
clearly very much at early stages, much like the pros-
pect of their constructive integration advocated in the
literature.13,55
Given the ‘infancy’ of the phenomenon, many
aspects of it are still fairly speculative, and this was
evident in interviews with participants, which elicited
differing views on the same aspects. As a methodolog-
ical reflection, having multiple participants confronting
each other at once in group discussions (compared with
our individual interviews) might have produced further
insights into the issue.31,32 FGs were part of the origi-
nal plan for this study, however, participant recruit-
ment practicalities determined that it was not possible
to organise such sessions; perhaps a limitation.
Another limitation might lie within the sample as its
selection was non-random. Participants chose to volun-
teer their insights, a factor which could potentially have
introduced some level of bias in the findings.
Moreover, all but two of the nine participants were
personal/professional contacts of the researchers,
which might have positively influenced their decision
to take part in the study.56 Most participants were
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early adopters of commercial DHTs themselves, hence
personal awareness and interest might have played a
role in their decision to volunteer and offer their
insights, which may well differ from those of the gen-
eral population of HCPs. This is further highlighted by
the fact that one of the perceived barriers towards
implementation was colleagues’ mindsets. Most partic-
ipants were from (or at least practiced within) the UK,
except for the ‘GH Expert’. This clearly restricts,
though does not categorically preclude, the relevance
of this study beyond the UK. The number of partici-
pants was also relatively small, therefore, while most
themes recurred between participants, suggesting data
saturation was achieved within our sample, we cannot
be sure this is the case in the general population of
HCPs, who may have even less experience with
DHTs (personal or with patients). Nevertheless, the
variety of both experts interviewed, and of relevant
aspects touched on during the interviews, undoubtably
enrich understanding, much like other qualitative work
with just as many participants.57 Moreover, the con-
cept of data saturation based on pre-set numbers,
whilst valid in most instances, still remains a relative
concept. This is demonstrated, for example, by Guest
et al. who conducted a similar interview-based qualita-
tive study in which data saturation was almost reached
by the sixth interview out of sixty conducted in total,
the bulk of which contributed very little new and rele-
vant material.58,59 A strength of this study is the deeper
level of insight acquired through participants, because
of its qualitative nature and the adoption of semi-
structured interviews which facilitated data generation
around relevant themes and concepts.60,61 Some of
these themes were in line with the recent literature,
which also suggests that potential selection bias might
have only minimally influenced our findings.
Given these findings, it appears premature to foresee
the imminent implementation of DHTs in healthcare.
However, this does seem to be the ‘general direction of
travel’ and examples are: a) the already mentioned
‘NHS Apps Library’, 34 which suggest awareness of
the popularity and the impact that commercial DHTs
can have on patients; b) a recent partnership between
Amazon AlexaVR and the NHS,62 whereby answers to
health-related questions from consumers in the UK will
be sought from official NHS websites; c) the recent
WHO guidelines for digital health interventions, advo-
cating for the use of smartphone-based technologies as
these are recognised to be well-spread in both devel-
oped and developing settings;5 and d) sustainable sol-
utions aimed at providing the public with healthcare
support via mainstream digital means, e.g. smart-
phones and apps, are clearly a main element on the
agenda of HCPs involved in DHTs innovation, as
gathered from the latest ‘Digital Catalyst’ event in
Newcastle.63
At the time of conducting the research, it seemed
premature according to our participants to focus on
DHT experiences as most of the participants had not
used DHTs with their CV patients. Early adopter, tech-
enthusiast HCPs formed the majority of our sample
and their interest in our study seemed to derive from
their own personal experiences of DHTs rather than
their experiences of working with CV patients. It was
considered that DHTs were not mainstream enough
yet, that there was little evidence for practice and that
guidelines were in their infancy. These findings may
help to explain why there is a dearth of qualitative
studies of HCPs’ perceptions towards self-tracked CV
health-related outputs as indicated in our introduction.
Our work therefore contributes to the knowledge gap,
however, this is only to report a lack of experience
among our sample at this stage and cannot inform
practice. We anticipate that the use of DHTs among
CV patients will grow over the coming years and that
the clinical implications will need to be researched. We
also note that the impact of the COVID-19 pandemic,
which began after the conclusion of our data collection
and analysis, has led to speculation about increased
reliance on DHTs and a rapid acceleration in the use
of DHTs in clinical practice, including for CV patients,
and therefore this unprecedented event will have policy
and practice in unanticipated ways that need to be
better understood in general and in relation to CV
patients.64–66
Finally, further advancements are needed before
integration of commercial DHTs can take place safely
and constructively in healthcare. To achieve this,
having explored HCPs’ perspectives and concerns on
the issue, more research is warranted on several differ-
ent aspects to: overcome the identified barriers; mini-
mise the disadvantages; and assess the feasibility and
effectiveness of these technologies in aiding universal
healthcare provision, as in the UK’s NHS. A variety of
different methodological approaches will be needed.
For example, more focused and patient-oriented inter-
vention studies assessing feasibility and effectiveness of
commercial DHTs in managing specific conditions, e.g.
cardiovascular diseases or diabetes, applying a rapid
cycle evaluation methodology,67 may help address
these gaps. Future studies should also aim to gather
and take into account different patients’ views, experi-
ences and considerations. Understandably, though,
there are limitations towards rigorous study design
and sustainable scaling up of interventions once
deemed effective, e.g. resources availability, or lack
thereof.68 Pursuing a practical partnership between
healthcare and private digital technology companies,
to establish common grounds and acceptable
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compromises between differing agendas, may be a valid
starting point.
Conclusions
Digital solutions undoubtably offer many opportuni-
ties for health care and promotion. Successful, safe and
constructive integration of patient-owned DHTs into
the digital healthcare systems available to HCPs is in
its infancy and needs further work to assess and mea-
sure the effectiveness and, possibly, realise its potential
in the near future. The challenges ahead are neverthe-
less substantial and further research should focus on
addressing the disadvantages, minimising the identified
barriers and finding long-term, safe and sustainable
solutions for the implementation of technologies des-
tined to increase in popularity and relevance.
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Appendix 1. Data analysis framework.









DH tech mentions Wearables
Apps
Other
Experience with patients/clients Yes
Some
No
Attitudes towards DH tech & patients Positive
Negative
(continued)
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Appendix 1. Continued
Main theme Code Sub-code








Patient autonomy Patient digital (il)literacy
Data gaming
Data security Business data VS NHS data ownership and usage
Inequality concerns
Data obsession






Heath in the digital/online
environment
Trusted sources NHS Apps Library (approved apps)
Social media
Other (e.g. blogs or specific websites)
Evidence-based information VS personal opinion
Barriers towards implementation Patient digital literacy Age-associated digital illiteracy (ve attitude from
potential users who could benefit the most)
Cost for patients (devices AND specific apps)
Cost for NHS
Software/hardware failure
Quick obsolescence of new tech
Patient compliance






Future Overall technological advancements and its consequences
Direction of future research
þve aspects
ve aspects
Deviant themes Data-secure translation services to overcome language bar-
riers in a multicultural society such as the Scottish one
Barrier or opportunity? (e.g. for a new market/research
area)
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